1167 related articles for article (PubMed ID: 12907632)
21. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
Sheils OM; O'Leary JJ; Sweeney EC
J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
[TBL] [Abstract][Full Text] [Related]
22. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE
Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
24. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
[TBL] [Abstract][Full Text] [Related]
25. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
[TBL] [Abstract][Full Text] [Related]
26. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
28. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
29. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
30. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
[TBL] [Abstract][Full Text] [Related]
31. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
[TBL] [Abstract][Full Text] [Related]
32. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
Nakazawa T; Kondo T; Kobayashi Y; Takamura N; Murata S; Kameyama K; Muramatsu A; Ito K; Kobayashi M; Katoh R
Cancer; 2005 Sep; 104(5):943-51. PubMed ID: 16015630
[TBL] [Abstract][Full Text] [Related]
33. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
Frattini M; Ferrario C; Bressan P; Balestra D; De Cecco L; Mondellini P; Bongarzone I; Collini P; Gariboldi M; Pilotti S; Pierotti MA; Greco A
Oncogene; 2004 Sep; 23(44):7436-40. PubMed ID: 15273715
[TBL] [Abstract][Full Text] [Related]
34. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.
Muzza M; Degl'Innocenti D; Colombo C; Perrino M; Ravasi E; Rossi S; Cirello V; Beck-Peccoz P; Borrello MG; Fugazzola L
Clin Endocrinol (Oxf); 2010 May; 72(5):702-8. PubMed ID: 20447069
[TBL] [Abstract][Full Text] [Related]
35. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutations in papillary thyroid carcinoma.
Wojciechowska K; Lewinski A
Endocr Regul; 2006 Dec; 40(4):129-38. PubMed ID: 17201587
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
38. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas.
Lima J; Trovisco V; Soares P; Máximo V; Magalhães J; Salvatore G; Santoro M; Bogdanova T; Tronko M; Abrosimov A; Jeremiah S; Thomas G; Williams D; Sobrinho-Simões M
J Clin Endocrinol Metab; 2004 Sep; 89(9):4267-71. PubMed ID: 15356020
[TBL] [Abstract][Full Text] [Related]
39. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
[TBL] [Abstract][Full Text] [Related]
40. RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas?
Musholt PB; Imkamp F; von Wasielewski R; Schmid KW; Musholt TJ
Surgery; 2003 Dec; 134(6):881-9; discussion 889. PubMed ID: 14668719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
